ETS-related gene (ERG) expression as a predictor of oncological outcomes in patients with high-grade prostate cancer treated with primary androgen deprivation therapy: a cohort study. by Rezk, Mark et al.
1Rezk M, et al. BMJ Open 2019;9:e025161. doi:10.1136/bmjopen-2018-025161
Open access 
ETS-related gene (ERG) expression as a 
predictor of oncological outcomes in 
patients with high-grade prostate cancer 
treated with primary androgen 
deprivation therapy: a cohort study
Mark Rezk,  1,2 Ashish Chandra,3 Daniel Addis,3 Henrik Møller,4 Mina Youssef,5,6 
Prokar Dasgupta,1 Hide Yamamoto7,8
To cite: Rezk M, Chandra A, 
Addis D, et al.  ETS-related 
gene (ERG) expression as 
a predictor of oncological 
outcomes in patients with 
high-grade prostate cancer 
treated with primary androgen 
deprivation therapy: a 
cohort study. BMJ Open 
2019;9:e025161. doi:10.1136/
bmjopen-2018-025161
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
025161).
Received 2 July 2018
Revised 12 October 2018
Accepted 3 January 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Mark Rezk;  mrezk@ nhs. net
Research
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Objectives To determine whether ETS-related gene (ERG) 
expression can be used as a biomarker to predict biochemical 
recurrence and prostate cancer-specific death in patients with 
high Gleason grade prostate cancer treated with androgen 
deprivation therapy (ADT) as monotherapy.
Methods A multicentre retrospective cohort study 
identifying 149 patients treated with primary ADT for 
metastatic or non-metastatic prostate cancer with Gleason 
score 8–10 between 1999 and 2006. Patients planned 
for adjuvant radiotherapy at diagnosis were excluded. 
Age at diagnosis, ethnicity, prostate-specific antigen and 
Charlson-comorbidity score were recorded. Prostatic 
tissue acquired at biopsy or transurethral resection surgery 
was assessed for immunohistochemical expression of 
ERG. Failure of ADT defined as prostate specific antigen 
nadir +2. Vital status and death certification data 
determined using the UK National Cancer Registry. Primary 
outcome measures were overall survival (OS) and prostate 
cancer specific survival (CSS). Secondary outcome was 
biochemical recurrence-free survival (BRFS).
results The median OS of our cohort was 60.2 months 
(CI 52.0 to 68.3). ERG expression observed in 51/149 
cases (34%). Multivariate Cox proportional hazards 
analysis showed no significant association between ERG 
expression and OS (p=0.41), CSS (p=0.92) and BRFS 
(p=0.31). Cox regression analysis showed Gleason score 
(p=0.003) and metastatic status (p<1×10-5) to be the only 
significant predictors of prostate CSS.
Conclusions No significant association was found 
between ERG status and any of our outcome measures. 
Despite a limited sample size, our results suggest that ERG 
does not appear to be a useful biomarker in predicting 
response to ADT in patients with high risk prostate cancer.
IntrOduCtIOn 
The development of castration resistance is a 
major clinical hurdle in patients with advanced 
prostate cancer and is taken as a marker of 
impending mortality. Early identification of 
patients who develop castrate resistant prostate 
cancer can be clinically useful in enabling early 
aggressive treatment and therefore in reducing 
cancer-related deaths.
A recurrent gene fusion event involving the 
3’ end of ERG (ETS-related gene) to 5’ TMPRSS2 
(transmembrane protease, serine 2)1 is one of the 
most frequently occurring genetic aberra-
tions in prostate cancer2 but its prognostic 
value is still being explored.3 A meta-analysis 
evaluating the role of TMPRSS2:ERG fusion 
protein in patients undergoing radical prosta-
tectomy found no association with biochem-
ical recurrence or lethal disease.4
Given that TMPRSS2:ERG is androgen 
regulated,5 its association with oncological 
outcomes in patients treated with androgen 
deprivation therapy (ADT) is possible. ERG 
expression inversely correlates with the levels 
of androgen receptor protein in the cell and 
may exert a selective pressure for the devel-
opment of a castrate-resistant state.6 Further-
more, androgen-regulated ERG expression 
strengths and limitations of this study
 ► This observational study consists of a large cohort 
of solely high-risk cancers treated with initial andro-
gen deprivation therapy (ADT) as monotherapy with 
subsequent vital status determination through a UK 
national death certification registry.
 ► The association between ETS-related gene (ERG) 
expression and oncological survival is explored for 
the first time in patients on ADT as monotherapy.
 ► Our study population is of limited sample size. 
Accuracy of results may be reduced from lack 
of covariates gained through retrospective data 
collection.
 ► Determination of ERG status is limited to immuno-
histochemical detection of the protein without clas-
sification of its mutation at a genomic level.
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appears to persist following the development of castration 
resistance.7
In vivo validation of ERG’s metastatic influence has 
been controversial. Scheble VJ et al had shown a greater 
proportion of castration resistant metastatic prostate 
cancer driven by ERG negative tumours,8 while Perner S 
et al had observed a greater predilection to metastases in 
fusion positive foci.9
The aim of this study is to explore a possible association 
between ERG expression status and oncological outcomes 
in high grade and advanced prostate cancer patients 
treated by ADT as monotherapy. The primary end points 
are overall survival (OS) and prostate cancer specific 
survival (CSS). The secondary end point is biochemical 
recurrence-free survival (BRFS).
PAtIents, MAterIAls And MethOds
data collection, study inclusion and exclusion criteria
Patients were identified from the pathology databases at 
two large neighbouring hospitals, Guy’s and St Thomas’ 
hospitals NHS Foundation Trust and King’s College 
Hospital NHS Foundation Trust in London, UK, between 
January 1999 and August 2006. All patients treated with 
primary ADT were included in the study. Those were iden-
tified among patients with a total Gleason score of 8–10. 
For each patient, the initial assigned treatment was iden-
tified using electronic and paper records. Patients with 
both metastatic and non-metastatic disease were included 
in the study. Clinical data collected included the age at 
diagnosis, the assigned treatment at diagnosis, ethnicity 
(Caucasian, Afro-Caribbean, or other), Charlson comor-
bidity score,10 date of diagnosis, total modified Interna-
tional Society of Urologic Pathology 2005 Gleason Score, 
radiological evidence of metastasis at diagnosis, history of 
previous prostate cancer treatment, and serial prostate 
specific antigen (PSA) values (ng/mL). Patients were 
excluded from the study for any missing data, if they did 
not receive ADT or were planned to receive other adju-
vant therapies such as radiotherapy. Data on unplanned 
adjuvant therapy following ADT were not collected due to 
incomplete follow-up data. The primary end points were 
OS and CSS. The secondary end point was BRFS.
Vital status and death certification data
Patient vital status data were retrieved from the National 
Cancer Registry in Public Health England.11 Following 
institutional approval, unique patient National Health 
Service numbers were linked to vital status, dates of 
death and ICD-10 codes on the immediate cause of death 
(cause 1a), other diseases or conditions leading to 1a 
(causes 1b and 1 c), underlying cause of death and other 
significant conditions not directly related to death (cause 
2).12 A prostate cancer death was defined as any death 
stating ‘Prostate Cancer’ in any of causes 1a, 1b, 1 c or an 
underlying cause. Biochemical recurrence was defined as 
an increase of more than 2 ng/mL from the PSA nadir 
value with censoring on the date when PSA rose more 
than 2 ng/mL above nadir.13
Prostate cancer sample collection, tissue processing and 
immunohistochemical staining
Prior to retrieval of archived prostate tissue samples, avail-
able H&E-stained slides were examined by two consultant 
histopathologists to select one tissue block for each patient 
based on the largest cancer volume. Specimen numbers 
were used to retrieve the corresponding paraffin-em-
bedded blocks from the archives, and 3 µm sections were 
cut from each block using the Rotary Microtome HM 32S. 
Immunohistochemistry was performed in batches using 
the Ventana BenchMark ULTRA IHC/ISH automated 
stainer (Ventana Medical Systems). Deparaffinisation of 
the sections was carried by warming up the slides at 72°C 
in Ventana EZ Prep solution. Endogenous peroxidase 
activity was blocked using the Ventana inhibition kit and 
antigen retrieval was carried out by incubating the slides 
in Cell Conditioning solution-1 and subsequently heating 
at 100°C for 8 min, then 100 µL of Anti-ERG (EPR3864) 
Rabbit Monoclonal Primary Antibody was applied on each 
slide for 32 min. Visualisation was performed using anti-
rabbit horseradish peroxidase (HRP)-labelled secondary 
antibody and 3,3'-diaminobenzidine tetrahydrochloride 
(DAB) chromogen (Roche/Ventana Ultra View DAB kit). 
The slides were washed and counterstained with Ventana 
Haematoxylin and Ventana Bluing Solution.
The IHC nuclear reactivity for ERG protein expression in 
the vascular endothelial cells was used as positive internal 
controls.14 Tests were repeated when endothelial cells failed 
to stain with ERG antibody (see supplementary figure 1).
h-scoring
Semiquantitative IHC analysis of ERG expression was 
conducted by the H-scoring system.14 Percentages of 
prostate cancer cells with positive and negative nuclear 
ERG staining were assessed at high magnification for each 
sample by two consultant histopathologists. The H-score 
was calculated as: 3× percentage cells with strong ERG 
expression +2×  percentage of cells with intermediate 
ERG expression +1×  percentage of cells with weak ERG 
expression.15 The total H-score per sample therefore 
ranged from 0 to 300. H-scores were classified as nega-
tive (0–50), weakly positive (51–100), moderately posi-
tive (101–200) or strongly positive (201–300) (see online 
supplementary figure 2).
Validation of antibody clone against an alternative anti-erG 
antibody
Alternative ERG staining was carried out on selected 
cancer tissue samples using an alternative monoclonal 
ERG antibody (clone 9FY, ab139431). The results are 
depicted on the photomicrographs shown in supplemen-
tary figure 3.
statistical methods
OS and CSS were determined using the Kaplan-Meier 
method. Univariate analysis of survival was performed 
 o
n
 Septem
ber 3, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025161 on 8 March 2019. Downloaded from 
3Rezk M, et al. BMJ Open 2019;9:e025161. doi:10.1136/bmjopen-2018-025161
Open access
using the log-rank method. Multivariable Cox propor-
tional hazards analysis was used to assess OS, CSS and 
BRFS with adjustments for ERG expression, age, ethnicity, 
Gleason score, PSA, presence of metastasis at presenta-
tion and Charlson comorbidity score. Statistical analyses 
were conducted using SPSS V.22, Graphpad Prism V.5.0 
and Microsoft Excel software.
Patient and public involvement
No patients and public persons were involved in the 
commencement of this research.
results
Cohort characteristics
A total of 527 patients with high Gleason score prostate 
cancer were diagnosed on biopsy, of which 169 patients 
were assigned to primary ADT as monotherapy. Exclusion 
of patients was due to tissue samples being unavailable 
(n=4), lack of vital status data output from the National 
Cancer Registry (n=4) or one or more missing clinical 
parameters (n=12). Complete data were available for 149 
patients which formed the study population.
Mean follow-up was 46.5 (±25.2) months. Fifty-nine 
patients (40%) had metastatic disease at presentation. 
The clinical characteristics of the cohort are shown in 
(table 1).
ERG expression was observed in 51 cases (34%), of 
which nearly all demonstrated strong ERG expression 
(92%) (figure 1), (intensity distribution of ERG staining 
shown in supplementary figure 4). No ERG expression 
was found in incidental benign acini within samples. 
ERG positivity was associated with older age, and Cauca-
sian ethnicity (when compared with Afro-Carribean and 
Other ethnic groups), but not Gleason score, initial PSA 
Table 1 Clinical characteristics of the study population stratified by ERG expression status (p values obtained by χ2 or 
*t-tests)
ERG negative % ERG positive % P value
(n=98) (n=51)
Mean age (±SD), years 72.3 (±8.3) 75.5 (±8.6) 0.03*
Ethnicity
  Caucasian 51 52 37 73 0.04
  Afro-Caribbean 41 42 11 22
  Other 6 6 3 6
Gleason score
  8 22 52 13 25 0.88
  9 71 42 36 71
  10 5 6 2 4
PSA (±SD), ng/mL 1378 (±10849) 283 (±1203) 0.48*
  <10.00 4 4 4 8 0.38
  10–19 17 18 7 14
  20–49 24 25 18 36
  50–99 13 13 10 20
  ≥100 39 40 11 22
Metastasis
  No 60 61 30 59 0.78
  Yes 38 39 21 41
Charlson comorbidity
  0 43 44 25 49 0.05
  1 30 31 6 12
  2 16 16 11 22
  ≥3 9 9 9 18
Follow-up (±SD), months 47.9 (±25.5) 43.7 (±24.9) 0.34
  Deaths
  All causes 46 47 28 55 0.39
  Prostate cancer specific 29 30 17 33 0.71
ERG, ETS-related gene; PSA, prostate-specific antigen. 
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level, or presence of metastatic disease at presentation 
(table 1).
national Cancer registry-linked oncological survival 
outcomes following primary androgen deprivation therapy in 
metastatic and non-metastatic high Gleason-grade prostate 
cancer
The National Cancer Registry was used to determine the 
vital status and death certification details for each patient. 
Seventy-five patients (50%) had died during follow-up, of 
whom 55 had died as a result of prostate cancer. Median 
OS for the cohort was 60.2 months. OS, CSS and BRFS for 
the cohort are shown (figure 2).
Presence of metastatic disease at diagnosis significantly 
affected OS (p=0.001), CSS (p<1×10-7) and BRFS (p<1×10-
6). Gleason score significantly affected OS (p=0.004) and 
CSS (p=0.004) but not BRFS (p=072). PSA at presenta-
tion only affected BRFS (p=1×10-5). Those associations 
were calculated using log-rank analysis.
Association of ets-related gene  expression and oncological 
outcomes in high risk cases treated by primary androgen 
deprivation therapy
Log-rank analysis was first conducted to determine 
whether ERG expression predicted oncological outcomes 
in the high-risk cohort stratified by ERG expression status 
(figure 3). No statistically significant association was 
observed between ERG expression and OS, CSS or BRFS.
Cox proportional hazards regression analysis was 
conducted to determine independent predictors of onco-
logical outcomes. Mutual adjustments were made for ERG 
expression, age, ethnicity, Gleason score, PSA, presence 
of metastasis at presentation and Charlson comorbidity 
(table 2). The presence of metastatic disease was signifi-
cantly associated with OS (HR 2.60, 95% CI 1.54 to 4.40), 
CSS (HR 4.51, 95% CI 2.36 to 8.60) and BRFS (HR 3.15, 
95% CI 1.93 to 5.16). Total Gleason score was significantly 
associated with OS (Gleason 9; HR 2.33, 95% CI 1.2 to 
4.53 and Gleason 10; HR 5.81, 95% CI 2.04 to 16.52, refer-
ence group Gleason 8) and CSS (Gleason 9; HR 2.56, 95% 
CI 1.13 to 5.83 and Gleason 10; HR 6.45, 95% CI 2.04 to 
16.52, reference group Gleason 8) but not BRFS. Age was 
significantly associated with OS only. We found no statisti-
cally significant association between ERG expression and 
OS, CSS or BRFS. The results did not change when ERG 
expression status was replaced with the H-score (results 
not shown).
dIsCussIOn
In this cohort, we examined the association of ERG expres-
sion with survival endpoints in patients treated by primary 
Figure 1 H-score distribution of ERG positive cases. 47/51 (92%) had a strongly positive H-score. ERG, ETS-related gene .
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ADT. Following multivariate analysis, we found no associ-
ation of ERG expression with OS, CSS or BRFS (table 2). 
Advances in planned adjuvant treatments for high-risk 
prostate cancer such as radiotherapy or chemotherapy 
confounds the assessment of biomarkers in patients 
receiving ADT in more recent cohorts. Linkage of clinical 
data was made with the National Cancer Registry which 
provided an up-to-date vital status on all patients residing 
in England.
ERG is commonly described as an oncogene although 
its ubiquitous expression in endothelial and haemato-
poietic stem cells suggest an essential role in angiogen-
esis, endothelial cell function and haematopoiesis.16 17 
Since the discovery of the ERG and androgen regulated 
Figure 2 Oncological outcomes of high-risk prostate cancer following primary androgen deprivation therapy. Significant 
associations shown in bold. BSPositive, bone scan positive.
Figure 3 Kaplan-Meier survival curves stratified by ERG expression status for OS, CSS and BRFS.
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TMPRSS2 genetic fusion in prostate cancer,1 its role 
as a sensitive and prevalent marker for prostate cancer 
has been shown to be highly replicable.4 Recent whole 
genome sequencing studies have revealed it to be the most 
frequent genetic aberration in prostate cancer within the 
entire genome.2 Its high prevalence among all grades of 
disease4 18–21 however, supports its significance to be a 
marker of cancer per se rather than a marker for prog-
nosis. ERG overexpression in animal models produces 
prostate intraepithelial neoplasia but not invasive cancer, 
suggesting it to be an early event in the natural history of 
prostate cancer.22
Androgen receptor is known to play a role in the devel-
opment of castrate resistance in prostate cancer5 and its 
levels have been shown to correlate with ERG expression.6 
To the best of our knowledge, only a few studies have 
looked into the possible association of primary ADT on 
ERG positive cancer with varying conclusions.23–25 Similar 
to the findings of our study, Berg et al suggest no asso-
ciation between ERG expression and the development 
of castrate resistance in patients treated with primary 
ADT.24 Huang et al had shown that combined ERG and 
androgen receptor status was significant in its association 
with a worsened survival in prostate cancer.23 However, 
sole expression of ERG had not conferred worsened 
survival outcomes in patients with prostate cancer. Graff 
et al suggest a protective benefit in managing ERG positive 
prostate cancer with ADT.25
Our study is the largest cohort of solely high-risk cancers 
homogeneously treated with initial ADT as planned 
monotherapy with subsequent high-quality vital status 
determination through a national registry.
In organ confined prostate cancer, ERG expression 
and its association with clinical outcomes has been the 
subject of numerous studies with conflicting outcomes.3 26 
A meta-analysis describing ERG fusion positive cancer 
and its associated outcomes in postprostatectomy showed 
ERG fusion events to be associated with a higher clinical 
stage at diagnosis of T3 over T2 with a risk ratio of 1.23, 
yet no association was found for cancer specific survival or 
disease recurrence.4
Although we used IHC to estimate TMPRSS2:ERG gene 
fusion status, studies have shown very high concordance 
between more accurate fluorescence in situ hybridization 
(FISH) techniques.27–30 The reproducibility of the tech-
nique was assessed using an additional antibody clone, 
as well as determining technical success for each sample 
using endothelial cell expression as internal controls 
(supplementary figures 1 and 3). The prevalence (34%) 
of ERG expression is in line with previous studies.4 The 
association between Caucasian ethnicity and ERG expres-
sion agrees with a previous study evaluating TMPRSS2:ERG 
fusion events.31 Higher age was significantly associated 
with ERG expression in our cohort (p=0.03), in contrast to 
other studies that showed a higher proportional expres-
sion in the younger men32 or no correlation at all.4 14 It is 
Table 2 Multivariate Cox proportional hazards analysis of ERG expression with other known oncological outcome parameters
P value HR
95% CI
P value HR
95% CI
P value HR
95% CI
Lower Upper Lower Upper Lower Upper
ERG expression 0.41 1.24 0.74 2.05 0.92 1.03 0.57 1.87 0.31 0.78 0.47 1.27
Age 0.02 1.04 1.01 1.07 0.19 1.02 0.99 1.06 0.82 1.00 0.97 1.03
Ethnicity
  Caucasian (ref) 0.75 0.98 0.44
  Afro-Caribbean 0.70 0.90 0.53 1.53 0.86 0.94 0.51 1.75 0.52 0.85 0.52 1.38
  Other 0.57 1.35 0.47 3.86 0.93 0.94 0.22 4.10 0.24 0.49 0.15 1.59
Gleason score
  8 (ref) 0.003 0.01 0.79
  9 0.01 2.33 1.20 4.53 0.02 2.56 1.13 5.83 0.50 1.20 0.71 2.01
  10 <0.001 5.81 2.04 16.52 <0.01 6.45 1.92 21.71 0.73 1.24 0.35 4.38
PSA 0.92 1.00 1.00 1.00 0.96 1.00 1.00 1.00 0.88 1.00 1.00 1.00
Metastasis <0.001 2.60 1.54 4.40 <1×10-5 4.51 2.36 8.60 <1×10-5 3.15 1.93 5.16
Charlson 
comorbidity
  0 (ref) 0.15 0.48 0.83
  1 0.19 1.52 0.81 2.87 0.85 1.08 0.50 2.35 0.56 1.18 0.68 2.07
  2 0.06 1.81 0.97 3.39 0.67 1.18 0.56 2.47 0.75 0.90 0.49 1.67
  ≥3 0.09 2.00 0.89 4.47 0.12 2.17 0.81 5.84 0.51 1.29 0.60 2.75
Reference groups are indicated for categorical variables.
BRFS, biochemical recurrence-free survival; CSS, cancer specific survival; ERG, ETS related gene;  OS, overall survival; PSA, prostate 
specific antigen. 
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possible that this is an association seen only in high grade 
prostate cancer cases.
limitations
The retrospective nature of the study had resulted in a 
reduction in the collection of other covariates such as 
stage at diagnosis.4
Moreover, a subset of patients within the cohort received 
unplanned adjuvant therapy in addition to androgen 
deprivation monotherapy which may have influenced 
the OS. This was not assessed as a covariate due to the 
heterogeneous nature of the treatment and small patient 
numbers.
Patients who did not have a complete dataset were 
excluded from the study although this had represented 
a small proportion of patients (20/169). In addition, 
despite being the largest cohort of patients solely treated 
with primary ADT, the sample size remains small reducing 
the power of this study population.
Both quantitative33 and qualitative differences in the 
ERG mutation have been implicated in prognostication 
of prostate cancer. Patients with cancer cells exhibiting an 
aberration consisting of both a duplication and deletion 
of the 5’ end of ERG (known as 2+ ‘Edel’) were predis-
posed to a poorer disease specific survival.34 35 In this 
context, the use of IHC was a limitation as it cannot detect 
the genomic fusion quantitatively or qualitatively but only 
isolated expression of the ERG protein.7 27 It is important 
to note that the H score does not provide a quantitative 
measurement of the ERG aberration.27 With this knowl-
edge at hand, subclassifications of ERG mutations when 
assessing prognostic indicators is recommended in future 
clinical studies. IHC may be controversial as a detection 
method of the TMPRSS2:ERG fusion gene. Sung JY et 
al expressed caution to its use for its false positive rate-
36while Gsponer and colleagues identified a subgroup of 
ERG genetic alterations that are undetectable at a protein 
level.37
COnClusIOn
While ERG expression is known to be strongly associated 
with oncogenesis, we show that ERG expression did not 
predict oncological survival in prostate cancer patients 
treated with ADT. Our findings are in line with other 
studies showing a lack of association between ERG expres-
sion and prostate cancer treatment outcomes.
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